Active — Not RecruitingPhase 2

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

Argentina213 participantsStarted 2024-11-15

Plain-language summary

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Prior history of in situ melanoma, basal or squamous cell skin cancer if treated with curative therapy.
✕. Patients with prostate cancer that are managed by surveillance.
✕. Patients with ductal carcinoma in situ, treated surgically with curative intent.
✕. Endothelin receptor antagonist
✕. Riociguat
✕. Prostacyclin or prostacyclin analogue
✕. Radiation to the lungs
✕. Oral corticosteroids \>15 mg/day

What they're measuring

Change in percent predicted forced vital capacity (ppFVC) compared to placebo

Timeframe: Baseline and Week 24

Trial details

NCT IDNCT06422884

SponsorEndeavor Biomedicines, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-10

View on ClinicalTrials.gov More Idiopathic Pulmonary Fibrosis trials